Definium Therapeutics, Inc. (DFTX)
Health Care ยท Medicinal Chemicals & Botanical Products
Definium Therapeutics, Inc. (DFTX) is listed on Nasdaq, where its shares have traded since March 3, 2020. SentiSense covers Definium Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Medicinal Chemicals & Botanical Products. Robert Barrow is its chief executive officer. The company reports 106 employees, and its corporate website is www.definiumtx.com.
About Definium Therapeutics, Inc.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 348 institutions reported holding DFTX, with 114.8 million shares worth $5.3 billion in aggregate. The largest reported holders were BlackRock, Capital Group and Avoro Capital Advisors. Of the 5 largest reported holders, 1 opened a new position in DFTX and 4 added shares during the quarter.
More on DFTX
- DFTX sentiment: whether news and social coverage of Definium Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- DFTX ownership: all 348 reporting institutions, plus insider and congressional trades.
- DFTX financials: revenue, net income, operating margin and free cash flow by quarter and year.
Frequently asked questions
What does Definium Therapeutics, Inc. do?
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction.
What sector is DFTX in?
SentiSense classifies Definium Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Medicinal Chemicals & Botanical Products.
Where does DFTX stock trade?
Definium Therapeutics, Inc. (DFTX) is listed on Nasdaq, where its shares have traded since March 3, 2020.
Who is the CEO of Definium Therapeutics, Inc.?
Robert Barrow is the chief executive officer of Definium Therapeutics, Inc..